Portfolio expansion solidifies company's
commitment to advancing cancer research and patient care
BURLINGTON, N.C., April 8,
2024 /PRNewswire/ -- Labcorp (NYSE: LH), a
global leader of innovative and comprehensive laboratory services,
announced today the strategic expansion of its precision oncology
portfolio, solidifying its commitment to advancing cancer research
and patient care on a global scale. The announcement underscores
Labcorp's dedication to investing in scientific, diagnostic and
laboratory innovations to support its pharmaceutical, biotechnology
and clinical research partners in bringing groundbreaking therapies
to market.
Labcorp continues to demonstrate its leadership in precision
oncology by expanding its portfolio of solutions that support the
development of novel therapies for oncology with the launch of its
proprietary platform for molecular residual disease (MRD),
Labcorp® Plasma Detect™, enhancement of its circulating
tumor DNA (ctDNA) genomic profiling solution Labcorp®
Plasma Complete™, and continued investment in expanding its
capabilities in cell and gene therapy.
"Labcorp is at the forefront of the evolution of precision
oncology, expanding the understanding and application of
biomarkers, enabling innovative technologies and platforms to
deliver improved genomic profiling solutions, and delivering
solutions designed to improve patient outcomes," said Dr.
Brian Caveney, Labcorp's chief
medical and scientific officer. "Our portfolio expansion enhances
our integrated services to empower our partners with the solutions
and support they need to advance their development programs and
make a lasting difference in patients' lives."
Introducing Labcorp Plasma Detect
Labcorp recently
announced the commercial availability of Labcorp Plasma
Detect, the first clinically validated, tumor-informed,
whole-genome sequencing circulating tumor DNA (ctDNA) MRD solution
for research and investigational use. This powerful solution
identifies patients at an increased risk of recurrence after
surgery or adjuvant chemotherapy (ACT) and is extensible to
clinical applications and can help enhance patient outcomes through
rapid, reliable analysis. Labcorp Plasma Detect validation
data will be presented at the American Association for Cancer
Research (AACR) annual meeting on April
9 in San Diego,
California.
Enhancing Labcorp Plasma Complete
Labcorp Plasma
Complete, a comprehensive next-generation sequencing (NGS)-based
ctDNA genomic profiling assay, has been enhanced with matched
analysis of white blood cells that enables identification of
germline variants and clonal hematopoietic (CH) variants that
confound most ctDNA-based profiling approaches. This research assay
enables the identification of clinically relevant variants across
521 genes, including SNVs, indels, bTMB, MSI, LOH, and select
amplifications and translocations.
Expanded Capabilities in Cell and Gene Therapy and
Development of Antibody Drug Conjugates
Labcorp's
deep scientific expertise and comprehensive solutions include
specialized pre-clinical discovery, biomarker and companion
diagnostics (CDx) development and post-commercialization
capabilities. Within this development-to-commercialization
continuum, cell and gene therapy is a growing focus of biopharma
pipelines, with more than 2,000 clinical trials in cell and gene
therapy globally representing approximately 20% of all biopharma
drugs in the pipeline and a total global investment of $11.7 billion.
Today, Labcorp supports 100% of FDA-approved CAR T-cell
therapies and more than 85% of all gene replacement therapies.
Further, and with the growing interest in antibody-drug conjugates
as cancer therapeutic agents to improve targeting to tumor cells,
Labcorp has supported collaborations and programs that have led to
87% of approved antibody drug conjugates (ADCs), 76% of which are
indicated for advanced clinical stages.
Labcorp's deep scientific, regulatory and market access
expertise and substantial reach into various patient populations
through an expansive diagnostic testing portfolio positions it as
the laboratory partner of choice for this transformative area of
medicine, enabling the acceleration of novel, advanced, and
targeted therapy development, rapidly advancing patient care from
day one post-approval and beyond.
To learn about Labcorp's oncology solutions, visit
https://oncology.labcorp.com/biopharma-partners.
About Labcorp
Labcorp (NYSE: LH) is a global
leader of innovative and comprehensive laboratory services that
helps doctors, hospitals, pharmaceutical companies, researchers and
patients make clear and confident decisions. We provide insights
and advance science to improve health and improve lives through our
unparalleled diagnostics and drug development laboratory
capabilities. The company's more than 67,000 employees serve
clients in approximately 100 countries, provided support for 84% of
the new drugs and therapeutic products approved in 2023 by the FDA,
and performed more than 600 million tests for patients around the
world. Learn more about us at www.labcorp.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-expansion-of-precision-oncology-portfolio-to-support-pharmaceutical-biopharma-and-clinical-research-in-advancing-drug-development-programs-302110293.html
SOURCE Labcorp